Data sourced from Dakota Private Markets, the private fund performance platform powered by Dakota. Learn More | Request Access
For deal sourcers, staying current on private company activity is critical to spotting active buyers, tracking market trends, and uncovering emerging investment opportunities ahead of competitors.
In September alone, we added more than 2,700+ new private company transactions, bringing the total to over 32,000+ searchable deals across sectors, industries, and transaction types in Dakota Private Markets
Inside Dakota Private Markets, you’ll find the transactions tab that provides structured, filterable data on deal types, values, and dates, while our editorial team curates daily updates through the Dakota transactions newsletter, helping you cut through the noise and focus on what matters most.
To ensure the most comprehensive coverage of private market activity, Dakota’s team monitors over 10,000 websites including company websites, newswires, and numerous third-party news providers to capture and verify transaction data as it happens.
Below are the top 10 health care transactions.
- Transaction Date: 9/3/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $10.9B
AbbVie completed its acquisition of Apogee Therapeutics, a clinical-stage biotech developing antibodies for inflammatory diseases such as atopic dermatitis and asthma, for $135.11 per share in cash, or about $10.9 billion in equity value. Announced June 22, 2026, the deal adds lead asset zumilokibart (an IL-13 antibody with quarterly or twice-yearly dosing potential) and the APG273 asthma combination to AbbVie’s immunology portfolio. AbbVie expects the transaction to be accretive to adjusted EPS beginning in 2032.
- Transaction Date: 9/1/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $10B
Vertex completed its acquisition of Crinetics Pharmaceuticals on September 1, 2026, paying $85.00 per share in cash for a total equity value of about $10.0 billion, or $8.8 billion net of cash acquired. The deal adds PALSONIFY, the first once-daily oral therapy for acromegaly, and atumelnant, in Phase 3 for congenital adrenal hyperplasia, which together could exceed $5 billion in peak annual revenue. Vertex expects it to become accretive to non-GAAP operating income in 2029, and it was financed with cash on hand and debt backed by $4.5 billion of committed bridge financing.
- Transaction Date: 9/16/2026
- Industry: Pharmaceuticals
- Type: Growth Equity
- Transaction Value: $3.4B
Apollo-managed funds, with KKR joining as a significant minority participant, closed a €3 billion capital solution for Bayer, announced July 10, 2026. The investors put equity into a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business, while Bayer keeps a majority stake and full operational control with no change to the LARC strategy. Centerview Partners advised the Apollo funds.
- Transaction Date: 9/11/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $2.8B
Eli Lilly completed its acquisition of AtaiBeckley, a clinical-stage developer of rapid-acting neuroplastogens for mental health conditions, led by BPL-003 for treatment-resistant depression. The July 16, 2026 deal paid $6.75 per share in cash, about $2.8 billion in equity value, plus a contingent value right of up to $2.50 per share (about $1.0 billion) tied to development and regulatory milestones for BPL-003 and VLS-01. BPL-003 holds FDA Breakthrough Therapy Designation and has initiated Phase 3 activities.
- Transaction Date: 9/28/2026
- Industry: Biotechnology
- Type: Growth Equity
- Transaction Value: $2B
AstraZeneca completed a $2.0 billion strategic equity investment in Summit Therapeutics, purchasing about 108,955 shares of convertible preferred stock that convert into common at a 1:1,000 ratio, equivalent to $18.36 per common share and a premium to the closing price on the announcement date. The funds will accelerate development of ivonescimab, a PD-1/VEGF bispecific antibody, across solid tumors, including combinations with antibody drug conjugates such as Sone-Ve and Datroway.
Want to track health care deal activity like this as it happens? Explore the full transactions tab in Dakota Private Markets for real-time, filterable data on every deal in this sector.
- Transaction Date: 9/21/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $1.25B
Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich, a radioisotope manufacturer and radiopharmaceutical developer, for USD 1.65 billion upfront on a cash-free/debt-free basis. That is about USD 1.25 billion in Telix shares, USD 302 million of assumed net debt, and USD 96 million of management rollover and transaction expenses, plus up to USD 700 million in contingent payments tied to ITM-11 approvals and sales. ITM generated USD 273 million of revenue in 2025, and Telix shareholders will own about 76.3% of the combined company. The deal is expected to close by the end of FY 2026, subject to Telix shareholder vote (expected November 2026) and regulatory approvals.
- Transaction Date: 9/23/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $929M
Zymeworks completed its acquisition of Theravance Biopharma, paying USD 17.00 per share in cash, a total transaction value of about USD 929 million, with a contingent value right also referenced in counsel’s description. The deal adds YUPELRI, the only approved nebulized once-daily LAMA for COPD, along with a 35% U.S. net profit share that generated USD 266.6 million in 2025 U.S. net sales. Zymeworks financed it with a USD 350 million non-recourse note from OMERS Life Sciences, about USD 219 million of its own cash, and Theravance’s roughly USD 360 million of net cash at closing.
- Transaction Date: 9/15/2026
- Industry: Biotechnology
- Type: Acquisition/Merger
- Transaction Value: $820M
Jazz Pharmaceuticals completed its acquisition of privately held Actio Biosciences for USD 820 million upfront, making Actio a wholly owned subsidiary. The deal centers on ABS-1230, an oral KCNT1 inhibitor for KCNT1-related epilepsy that has Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the FDA. As part of the transaction, Actio spun out its other programs into a new independent company funded by existing investors, with Jazz receiving a minority stake and certain related rights.
- Transaction Date: 9/1/2026
- Industry: Health Care Equipment & Supplies
- Type: Growth Equity
- Transaction Value: $700M
Medtronic announced a strategic partnership with Cornerstone Robotics, a surgical robotics company, backed by an investment of approximately USD 700 million that includes rights to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where it is approved. Sentire will be sold alongside Medtronic’s Hugo robotic-assisted surgery system, giving Medtronic a two-platform portfolio. Sentire received a CE Mark in May 2026 and is also approved in China and Singapore.
- Transaction Date: 9/28/2026
- Industry: Health Care Equipment & Supplies
- Type: Buyout/Private Equity
- Transaction Value: $663.7M
Webster Equity Partners agreed to acquire Lifecore Biomedical, a CDMO, in a transaction valued at up to USD 663.7 million assuming full achievement of performance milestones. Common stockholders will receive USD 6.28 per share in cash, a 49.5% premium, plus a contingent value right. Series A preferred holders receive their Conversion Amount in cash (about USD 50.2 million as of June 30, 2026) plus CVRs. Together the CVRs are worth up to USD 160 million, which could lift total consideration to USD 9.67 per common equivalent, a 130.2% premium.
At Dakota, we understand how important it is to stay current on deal activity as it happens. That’s why our editorial team continuously monitors the news for real-time updates on platform investments, add-ons, divestitures, and more to deliver daily highlights straight to your inbox through our transactions newsletter.
Inside Dakota Private Markets, the transactions tab provides structured, filterable data with deal dates, types, sectors, and financials, allowing you to build a customized feed that aligns with your focus areas.
Whether you're evaluating a new investment opportunity or tracking trends within a target sector, Dakota helps you cut through the noise and focus on what matters most.
For more information on these transactions and a deeper dive into their industries and sub-industries, request access to Dakota Private Markets.
